{"nctId":"NCT02243293","briefTitle":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection","startDateStruct":{"date":"2014-09-19"},"conditions":["Chronic Hepatitis C","Hepatitis C Virus"],"count":694,"armGroups":[{"label":"Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm B","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm C","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530","Drug: ribavirin (RBV)"]},{"label":"Arm D","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm E","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm F","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530","Drug: ribavirin (RBV)"]},{"label":"Arm G","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm H","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm I","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm J","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm K","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm L","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm M","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm N","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530","Drug: ribavirin (RBV)"]},{"label":"Arm O","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530"]},{"label":"Arm P","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493","Drug: ABT-530","Drug: ribavirin (RBV)"]},{"label":"Arm Q1","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]},{"label":"Arm Q2","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]},{"label":"Arm R1","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]},{"label":"Arm R2","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]},{"label":"Arm S1","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]},{"label":"Arm S2","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]}],"interventions":[{"name":"ABT-493","otherNames":["glecaprevir"]},{"name":"ABT-530","otherNames":["pibrentasvir"]},{"name":"ribavirin (RBV)","otherNames":[]},{"name":"ABT-493/ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","MAVYRET"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Screening laboratory result indicating HCV Genotype 2, 3, 4, 5, or 6 infection.\n* Chronic HCV infection.\n* Participant had to be either HCV treatment-naïve or treatment-experienced.\n* Participant had to be documented as non-cirrhotic or as having compensated cirrhosis (GT3 only).\n\nExclusion Criteria:\n\n* History of severe, life-threatening or other significant sensitivity to any drug.\n* Female who was pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner was pregnant or planning to become pregnant during the study.\n* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.\n* Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).\n* HCV genotype performed during screening indicating co-infection with more than one HCV genotype.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"93.3","spread":null},{"groupId":"OG004","value":"93.3","spread":null},{"groupId":"OG005","value":"93.5","spread":null},{"groupId":"OG006","value":"83.3","spread":null},{"groupId":"OG007","value":"98.1","spread":null},{"groupId":"OG008","value":"94.3","spread":null},{"groupId":"OG009","value":"96.4","spread":null},{"groupId":"OG010","value":"100.0","spread":null},{"groupId":"OG011","value":"97.5","spread":null},{"groupId":"OG012","value":"90.9","spread":null},{"groupId":"OG013","value":"95.5","spread":null},{"groupId":"OG014","value":"95.7","spread":null},{"groupId":"OG015","value":"97.9","spread":null},{"groupId":"OG016","value":"93.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Genotype 2 (GT2) Direct-acting Antiviral Agents (DAA)-Naive Participants (in Part 4, Arm S1) With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) as Compared to Historical Control","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)","description":"SVR4 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 4 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"93.3","spread":null},{"groupId":"OG004","value":"93.3","spread":null},{"groupId":"OG005","value":"93.5","spread":null},{"groupId":"OG006","value":"93.3","spread":null},{"groupId":"OG007","value":"98.1","spread":null},{"groupId":"OG008","value":"96.2","spread":null},{"groupId":"OG009","value":"96.4","spread":null},{"groupId":"OG010","value":"100.0","spread":null},{"groupId":"OG011","value":"97.5","spread":null},{"groupId":"OG012","value":"95.5","spread":null},{"groupId":"OG013","value":"95.5","spread":null},{"groupId":"OG014","value":"95.7","spread":null},{"groupId":"OG015","value":"97.9","spread":null},{"groupId":"OG016","value":"98.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \\< LLOQ during treatment; confirmed increase of \\> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"3.2","spread":null},{"groupId":"OG006","value":"3.3","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"1.9","spread":null},{"groupId":"OG009","value":"0","spread":null},{"groupId":"OG010","value":"0","spread":null},{"groupId":"OG011","value":"0","spread":null},{"groupId":"OG012","value":"0","spread":null},{"groupId":"OG013","value":"0","spread":null},{"groupId":"OG014","value":"2.1","spread":null},{"groupId":"OG015","value":"0","spread":null},{"groupId":"OG016","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \\< LLOQ at the end of treatment, excluding reinfection.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"3.4","spread":null},{"groupId":"OG004","value":"6.7","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"7.1","spread":null},{"groupId":"OG007","value":"0.0","spread":null},{"groupId":"OG008","value":"2.0","spread":null},{"groupId":"OG009","value":"3.6","spread":null},{"groupId":"OG010","value":"0.0","spread":null},{"groupId":"OG011","value":"0","spread":null},{"groupId":"OG012","value":"9.1","spread":null},{"groupId":"OG013","value":"4.5","spread":null},{"groupId":"OG014","value":"2.2","spread":null},{"groupId":"OG015","value":"1.4","spread":null},{"groupId":"OG016","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Fatigue","Headache","Nausea","Diarrhoea","Upper respiratory tract infection"]}}}